Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by the provided FDA label excerpts, including severity (life-threatening/fatal), timing (as early as after the first dose through years), management (immediate discontinuation, emergency care, and permanent discontinuation unless an alternative etiology is identified), and symptom overlap with immediate post-injection reactions.
Category Scores
Accurate Statements
Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection.
Section 5.1 Anaphylactic Reactions: "Life-threatening and fatal anaphylaxis has been reported..."
Anaphylaxis can occur at any time following initiation, including as early as after the first dose and up to years after starting treatment.
Section 5.1 Anaphylactic Reactions: "from as early as after the first dose, up to years after initiation" and "at any time following initiation"
If an anaphylactic reaction occurs, treatment must be immediately discontinued and patients should seek immediate emergency medical care.
Section 5.1: "seek immediate emergency medical care"; "treatment... must be immediately discontinued"
Some signs and symptoms of anaphylactic reactions may overlap with those of immediate post-injection reactions.
Section 5.1: "Some signs and symptoms... may overlap" and Section 5.2: "may overlap"
Glatiramer acetate injection is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol and reactions have included anaphylaxis.
Section 4 Contraindications: "contraindicated... hypersensitivity to glatiramer acetate or mannitol" and "Reactions have included anaphylaxis."
Unsupported Statements
Contradictions
Important Omissions
The claim does not explicitly state the label instruction that glatiramer acetate injection must be permanently discontinued unless a clear alternative etiology is identified.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI includes the key urgent actions (emergency care and immediate discontinuation) and correct timing and overlap information; the main omission is not mentioning the label’s “permanently discontinue unless an alternative etiology is identified” language.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s “permanently discontinue unless a clear alternative etiology is identified” instruction.
Suggested Improvement
Add the label-specified requirement to permanently discontinue the drug unless a clear alternative cause is identified when anaphylaxis occurs.